Raffael Kurek

3.0k citations

39 papers · 2.2k indexed · 1 hit paper · h-index 18

Oncology top 2%
Molecular Biology top 10%
Pulmonary and Respiratory Medicine top 5%
Cancer Research top 5%
Immunology top 10%

Co-authors: D. Wallwiener Patricia S. Steeg Tanja Fehm Karl Sotlar Seth M. Steinberg Andreas M. Stark Robert J. Weil Diane Palmieri
Topics: Lung Cancer Treatments and Mutations (9 papers)HER2/EGFR in Cancer Research (7 papers)Colorectal Cancer Treatments and Studies (5 papers)
Cited by: Cancer Research Oncology Pulmonary and Respiratory Medicine
Journals: Journal of Clinical Investigation Journal of Clinical Oncology Cancer Research
Partner nations: Germany United States Spain

In The Last Decade

Raffael Kurek

39 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

2015 331 citations Nick Thatcher, Fred R. Hirsch et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Raffael Kurek

Since Specialization

Citations

This map shows the geographic impact of Raffael Kurek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raffael Kurek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raffael Kurek more than expected).

Fields of papers citing papers by Raffael Kurek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raffael Kurek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raffael Kurek. The network helps show where Raffael Kurek may publish in the future.

Co-authorship network of co-authors of Raffael Kurek

This figure shows the co-authorship network connecting the top 25 collaborators of Raffael Kurek. A scholar is included among the top collaborators of Raffael Kurek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raffael Kurek. Raffael Kurek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis 2018 ·Thrombosis Research ·(unknown),Luis Paz‐Ares,Nick Thatcher,David R. Spigel,Javad Shahidi,Victoria Soldatenkova,(unknown),Raffael Kurek,Frances A. Shepherd	6
2	EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study 2017 ·Journal of Thoracic Oncology ·Carlo Genova,Mark A. Socinski,Rebecca R. Hozak,Gu Mi,Raffael Kurek,Javad Shahidi,Luis Paz‐Ares,Nick Thatcher,Christopher J. Rivard,(unknown),Fred R. Hirsch	10
3	Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors 2016 ·Cancer Chemotherapy and Pharmacology ·David C. Smith,John D. Powderly,James J. Lee,Dale R. Shepard,Johan Wallin,Archana Chaudhary,(unknown),(unknown),Malcolm I. Mitchell,(unknown),Raffael Kurek,Patricia LoRusso	3
4	Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer 2016 ·Annals of Oncology ·Luis Paz‐Ares,Mark A. Socinski,Javad Shahidi,(unknown),Victoria Soldatenkova,Raffael Kurek,Marileila Varella‐Garcia,N. Thatcher,Fred R. Hirsch	54
5	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trialbreakdown → 2015 ·The Lancet Oncology ·Nick Thatcher,Fred R. Hirsch,Alexander Luft,Aleksandra Szczęsna,Tudor–Eliade Ciuleanu,Mircea Dediu,Rodryg Ramlau,Rinat Galiulin,Beatrix Bálint,György Losonczy,Andrzej Każarnowicz,Keunchil Park,Christian Schumann,Martin Reck,H. Depenbrock,Shivani Nanda,(unknown),Raffael Kurek,Luis Paz‐Ares,Mark A. Socinski	331
6	Pemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-small Cell Lung Cancer 2010 ·Journal of Thoracic Oncology ·Joan H. Schiller,Joachim von Pawel,Philipp Schütt,Rafat Ansari,Michael Thomas,Mansoor N. Saleh,Robert McCroskey,Wolfgang Pfeifer,Thomas Marsland,Goetz Kloecker,Martin Sebastian,Robert Pirker,Raffael Kurek,(unknown),Mark A. Socinski	45
7	Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study 2010 ·Annals of Oncology ·Sheela Rao,Naureen Starling,David Cunningham,Kate Sumpter,David Gilligan,Thomas Ruhstaller,Manuel Valladares‐Ayerbes,H. Wilke,Caroline Archer,Raffael Kurek,(unknown),J. Oates	86
8	Optimal treatment for patients with ectopic pregnancies and a history of fertility-reducing factors 2009 ·Archives of Gynecology and Obstetrics ·Sven Becker,Erich Solomayer,René Hornung,Raffael Kurek,Małgorzata Banyś,B. Aydeniz,H. B. G. Franz,D. Wallwiener,Tanja Fehm	15
9	Loss of Drop1 expression already at early tumor stages in a wide range of human carcinomas 2008 ·International Journal of Cancer ·Alexander Marmé,H Zimmermann,Gerhard Moldenhauer,Marina Schorpp‐Kistner,Claudia Müller,(unknown),(unknown),(unknown),(unknown),Eberhard Spieß,Andreas Hunziker,Faustino Merchán,Peter Möller,Uwe Hahn,Raffael Kurek,Frederik Marmé,G. Bastert,D. Wallwiener,Herwig Ponstingl	29
10	Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1 2008 ·Breast Cancer Research ·Hans Neubauer,Susan E. Clare,Wojciech Woźny,Gerhard Schwall,Slobodan Poznanović,Werner Stegmann,Ulrich Vogel,Karl Sotlar,D. Wallwiener,Raffael Kurek,Tanja Fehm,Michael A. Cahill	97
11	Her-2 Overexpression Increases the Metastatic Outgrowth of Breast Cancer Cells in the Brain 2007 ·Cancer Research ·Diane Palmieri,Julie L. Bronder,Jeanne M. Herring,Toshiyuki Yoneda,Robert J. Weil,Andreas M. Stark,Raffael Kurek,Eleazar Vega-Valle,Lionel Feigenbaum,Douglas Halverson,Alexander O. Vortmeyer,Seth M. Steinberg,Kenneth Aldape,Patricia S. Steeg	267
12	Progression-Specific Genes Identified by Expression Profiling of Matched Ductal Carcinomas In situ and Invasive Breast Tumors, Combining Laser Capture Microdissection and Oligonucleotide Microarray Analysis 2006 ·Cancer Research ·(unknown),Michael Bonin,Susan E. Clare,Kay Nieselt,Karl Sotlar,Michael Walter,Tanja Fehm,Erich Solomayer,Olaf Rieß,D. Wallwiener,Raffael Kurek,Hans Neubauer	191
13	Expression of Human Endogenous Gammaretroviral Sequences in Endometriosis and Ovarian Cancer 2006 ·AIDS Research and Human Retroviruses ·Lijuan Hu,Daniela Hornung,Raffael Kurek,(unknown),Jonas Blomberg,Agneta Bergqvist	21
14	The critical path method to analyze and modify OR‐workflow: Integration of an image documentation system 2006 ·Minimally Invasive Therapy & Allied Technologies ·(unknown),B. Aydeniz,D. Wallwiener,Raffael Kurek	5
15	Breast cancer proteomics by laser capture microdissection, sample pooling, 54‐cm IPG IEF, and differential iodine radioisotope detection 2006 ·Electrophoresis ·Hans Neubauer,Susan E. Clare,Raffael Kurek,Tanja Fehm,D. Wallwiener,Karl Sotlar,Alfred Nordheim,Wojciech Woźny,Gerhard Schwall,Slobodan Poznanović,(unknown),Christian Hunzinger,Werner Stegmann,André Schrattenholz,Michael A. Cahill	57
16	Influence of tumor biological factors on tumor cell dissemination in primary breast cancer. 2005 ·PubMed ·Tanja Fehm,Sven Becker,(unknown),B. Krämer,Ines Gruber,Karl Sotlar,Raffael Kurek,D. Wallwiener,Erich‐Franz Solomayer	18
17	Changes of serum HER2 status during clinical course of metastatic breast cancer patients. 2005 ·PubMed ·Tanja Fehm,W. Jäger,S. Kraemer,(unknown),(unknown),Erich‐Franz Solomayer,Raffael Kurek,D. Wallwiener,Gerhard Gebauer	16
18	Neoadjuvant Endocrine Therapy in Primary Breast Cancer 2004 ·Clinical Breast Cancer ·Jens Huober,U. Krainick‐Strobel,Raffael Kurek,D. Wallwiener	13
19	Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis 2003 ·Journal of Clinical Investigation ·Eva Tolosa,Weijie Li,Yoshiyuki Yasuda,Wolfgang Wienhold,Lisa Denzin,Alfred Lautwein,Christoph Driessen,Petra Schnorrer,Ekkehard Weber,Stefan Stevanović,Raffael Kurek,Arthur Melms,Dieter Brömme	104
20	Intermittierende Androgendeprivation 2000 ·Der Urologe ·U. W. Tunn,Nicholas Bruchovsky,H. Renneberg,J.M. Wolff,Raffael Kurek	4

About Raffael Kurek

Raffael Kurek is a scholar working on Oncology, Genetics and Cancer Research, having authored 39 papers that have together received 2.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (9 papers), HER2/EGFR in Cancer Research (7 papers) and Colorectal Cancer Treatments and Studies (5 papers). The work is most often cited by research in Cancer Research (563 citations), Oncology (1.0k citations) and Pulmonary and Respiratory Medicine (721 citations). Raffael Kurek has collaborated with scholars based in Germany, United States and Spain. Frequent co-authors include D. Wallwiener, Patricia S. Steeg, Tanja Fehm, Karl Sotlar, Seth M. Steinberg, Andreas M. Stark, Robert J. Weil, Diane Palmieri, Julie L. Bronder and Susan E. Clare. Their work appears in journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact